Faculty of Health Sciences

Permanent URI for this communityhttps://wiredspace.wits.ac.za/handle/10539/8707

For queries relating to content and technical issues, please contact IR specialists via this email address : openscholarship.library@wits.ac.za, Tel: 011 717 4652 or 011 717 1954

Browse

Subject: search.filters.subject.Prevalence

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Permanent denition caries in KwaZulu and Namibia 11-year-olds
    (1990) Hargreaves, J. A.; Cleaton-Jones, P.; Matejka, J.; et al
    The permanent dentitions of 11-year-old children in Namibia (n = 295) and KwaZulu (n = 308) living in rural and urban areas were examined using WHO caries diagnostic criteria. In low fluoride areas (less than 0.15 ppmF) significantly more caries was present in rural compared to urban KwaZulu but the prevalences in rural and urban Namibia were similar although significantly higher than in an area with 1.56ppmF in the drinking water. There was significantly more caries in rural Namibia than KwaZulu but the urban prevalences in both regions were similar. It is suggested that the urban findings are useful predictors for the needs of 11-year-old black children but local baseline surveys should be undertaken before considering dental programmes, treatment or preventive, for different rural communities in South Africa.
  • Thumbnail Image
    Item
    Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug - resistant TB
    (2014-01) Conradie, F; Mabiletsa, T; Sefoka, M; et al
    Background: Symptomatic symmetrical peripheral neuropathy (SSPN) is common in patients with HIV infection. It is also a common adverse event associated with both tuberculosis (TB) treatment and antiretroviral therapy (ART), particularly stavudine. While tenofovir is the one of recommended first-line nucleotide reverse transcriptase inhibitors (NRTIs), there is a risk of nephrotoxicity when using tenofovir together with the aminoglycosides needed to treat multidrug-resistant (MDR) TB. Thus, stavudine is often chosen as a treatment option for the HIV-infected MDR TB patient. Objective: To assess whether use of stavudine both before and during treatment for MDR TB increased the prevalence and incidence of SSPN. Method: MDR TB patients at Sizwe Tropical Disease Hospital were examined for signs of prevalent SSPN. Age, gender, HIV status, alcohol use, TB and HIV treatment regimens both prior to admission and current, and concomitant medications were recorded. Results: In this cohort of 246 patients, we found that 24.4% of patients with MDR TB had SSPN at time of admission for treatment of MDR TB. They were more likely to be HIV-infected (odds ratio (OR) 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) exposure to stavudine (OR 1.81; 95% CI 0.90 - 3.63). Incident SSPN occurred in 17% of patients and was associated with older age (hazard ratio (HR) 3.00; 95% CI 1.30 - 6.89) and exposure to terizidone (HR 2.98; 95% CI 0.94 to 4.61) or, to a lesser extent, with stavudine (crude HR 1.62; 95% CI 0.65 - 4.01) in the first 6 months of MDR TB treatment. This common adverse event emphasises the need for the development of less toxic drugs for the treatment of MDR TB.